Novo Nordisk, the Danish pharmaceutical giant behind obesity drug, Wegovy, has engaged Slingshot to develop and manage its ...

Novo Nordisk has signed an exclusive global licensing deal worth up to $2 billion for UBT251, a weight-loss drug developed by China-based The United Laboratories International Holdings Limited.

U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Novo Nordisk said on Monday it has become aware of several hundred units of counterfeit versions of its diabetes drug Ozempic ...

While much of the recent GLP-1 saga has been written in the U.S., Novo Nordisk continues to expand its semaglutide empire ...

Growth is driven by the rising prevalence of diabetes among the elderly, necessitating efficient insulin delivery solutions ...

The U.S. Food and Drug Administration is warning people of counterfeit versions of a popular weight loss drug are circulating ...

Novo Nordisk (NVO), the company behind Ozempic and Wegovy, announced that it will invest 6.4 billion reais (about $1.09 ...

The business-software group claimed the top spot as Europe’s largest company by market value, dethroning Wegovy maker Novo Nordisk.